T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients.
Phase 1
Not yet recruiting
- Conditions
- Metastatic Soft-tissue Sarcoma
- Interventions
- Drug: T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06474676
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias
Phase 1
Recruiting
- Conditions
- Relapsed Acute LeukemiaUndifferentiated LeukemiaBi-Phenotypic LeukemiaRefractory Acute Leukemia
- Interventions
- Drug: Hyper-CVAD
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06466395
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma
Not Applicable
Recruiting
- Conditions
- Unresectable Melanoma
- Interventions
- Other: Prebiotic Food-Enriched Diet
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 75
- Registration Number
- NCT06466434
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation
Recruiting
- Conditions
- Allogeneic Transplantation
- Interventions
- Behavioral: Patient Ancestry Questionnaires
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1200
- Registration Number
- NCT06450353
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).
Phase 2
Recruiting
- Conditions
- Locally Recurrent Oral Cavity Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT06448026
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
Phase 1
Recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT06448013
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT06445907
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Trial of Ubamatamab Alone or in Combination with Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
Phase 2
Recruiting
- Conditions
- SMARCB1-Deficient Malignancies
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06444880
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Phase 1
Recruiting
- Conditions
- Mutant IDH1 Inhibitor Olutasidenib
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 78
- Registration Number
- NCT06445959
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
Phase 1
Suspended
- Conditions
- FGFR2 FusionAdvanced Cholangiocarcinoma
- Interventions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT06439485
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath